Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection
about
Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyondMalaria parasite pre-erythrocytic stage infection: gliding and hidingSelection and refinement: the malaria parasite's infection and exploitation of host hepatocytesIn vivo CD8+ T cell dynamics in the liver of Plasmodium yoelii immunized and infected miceMalaria: progress, perils, and prospects for eradicationSSP3 is a novel Plasmodium yoelii sporozoite surface protein with a role in gliding motility.Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite ProteinA sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage developmentA nondiscriminating glutamyl-tRNA synthetase in the plasmodium apicoplast: the first enzyme in an indirect aminoacylation pathwayPlasmodium berghei histamine-releasing factor favours liver-stage development via inhibition of IL-6 production and associates with a severe outcome of diseasePreerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by designA Novel and Conserved Plasmodium Sporozoite Membrane Protein SPELD is Required for Maturation of Exo-erythrocytic FormsAMA1 and MAEBL are important for Plasmodium falciparum sporozoite infection of the liverMalaria parasites target the hepatocyte receptor EphA2 for successful host infectionComplete Plasmodium falciparum liver-stage development in liver-chimeric mice.Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes.The Ig domain protein CD9P-1 down-regulates CD81 ability to support Plasmodium yoelii infectionWhy functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites.Malaria parasite LIMP protein regulates sporozoite gliding motility and infectivity in mosquito and mammalian hosts.Malaria parasite development in the mosquito and infection of the mammalian host.Engineering of Genetically Arrested Parasites (GAPs) For a Precision Malaria VaccinePlasmodium P36 determines host cell receptor usage during sporozoite invasionPlasmodium protease ROM1 is important for proper formation of the parasitophorous vacuole.Advances and challenges in malaria vaccine development.Plasmodium berghei Δp52&p36 parasites develop independent of a parasitophorous vacuole membrane in Huh-7 liver cellsMalaria Parasite Liver Infection and Exoerythrocytic Biology.Host cell phosphatidylcholine is a key mediator of malaria parasite survival during liver stage infection.A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoitesPlasmodium Cysteine Repeat Modular Proteins 3 and 4 are essential for malaria parasite transmission from the mosquito to the host.The case for a rational genome-based vaccine against malaria.Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasitesImmunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoitesImmunization with genetically attenuated P52-deficient Plasmodium berghei sporozoites induces a long-lasting effector memory CD8+ T cell response in the liverDisruption of plasmepsin-4 and merozoites surface protein-7 genes in Plasmodium berghei induces combined virulence-attenuated phenotype.A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion.A new malaria antigen produces partial protection against Plasmodium yoelii challengeA combined transcriptome and proteome survey of malaria parasite liver stages.Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice.Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one?
P2860
Q20905953-676A5C00-74B1-47BD-842F-539E82AA6F82Q21032491-F4D361BD-C23F-4A3D-805D-9890B7C235D4Q27025899-B9ADA5BD-0429-4492-96C7-BCB341F537ACQ27310073-10EE5802-85E9-40CC-9AA2-A7B91D9A009CQ27485634-C9DBBC34-75F5-41DE-81B1-A69503BF09F9Q27973415-73110CE2-AFB1-4210-9434-B9B337AF403BQ27973488-DE0832C4-172E-4003-B65E-2BDF02AEA5DBQ27973897-A047C4F1-2CA5-430F-82B5-AAB4E7BD8E5BQ27976469-90399868-3221-4DD1-AFE7-25F16240EFF8Q30039017-E8868703-9027-410B-92B6-B34B2F0989F7Q30043830-922B0F43-8689-4161-BFEC-66A9F1D767DCQ30044206-7EF6E17D-7201-4DDC-A83F-0F1EEE9E4EC0Q30044955-4E2F26AA-EDED-474B-AC6A-CABD6C5F8164Q30047034-4E449FB6-46DD-498D-986B-F45A49A35CC7Q30525395-F750D739-7023-426C-94F6-96CA69994763Q33380159-18DB440A-5863-41DE-918E-923897892C27Q33553648-7516C5AA-C14F-43E4-9E0A-8DA12A2E7191Q33587443-929E1713-29DE-45F5-9485-DBA5F866B137Q33640306-81F863BC-017D-4F9D-A699-9E0CF6D461B3Q33708234-D6D7E560-55F2-4CCE-90C8-E7C01796237AQ33738231-B2C54DD3-BC4C-4D37-B421-A7DAB7D3F934Q33744460-6E2F1F32-CEB3-4A7E-BA75-4A2A7E2FBFB3Q33798033-B014A4AA-78F1-4158-AFA4-FCBA8D1941DFQ34016204-222EDB9C-87B9-452F-ADA2-6AE80FBF1386Q34145333-1A801321-3A2D-4110-A1B5-1A89BF998EF0Q34507085-C84EDCF2-F8B4-4A5E-A049-41F4D606704FQ34552223-2B1D94BF-7C9E-45D0-927A-822354551D2EQ34742789-72924A55-28C5-46A3-AB5F-FC5432CCBFD8Q34753532-AC020187-EED6-4FCD-AEE4-E4E72961FAAFQ34871838-52E3390F-E206-49D1-87CE-609F93E72C1DQ34999392-1B710BE0-F555-4D57-A9AA-CB67C7A1E552Q35051549-E1E548D1-E2F9-4939-A16E-BFEDF94E6625Q35111844-717005D9-FA15-4157-A329-BA91DECFD10BQ35509020-FEB69CD4-A9A8-43DE-9D9D-3F570FB991C8Q35551353-AF52E6BF-E855-40C3-B55B-78A922BDD3CAQ35618598-FFF80252-FA1E-48DE-AAA9-63ACDBD4AEEDQ36219507-5460499E-76EA-4D4C-A056-082044F2DAD5Q36423509-A0BD6A7E-B5A7-47F2-8E46-6C7FBA7D7ABDQ36483596-CA41C77C-A871-41E2-B180-C9983E608549Q36483682-15691857-5EA8-4CB0-BC3F-84DDF5AB34F7
P2860
Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Plasmodium yoelii sporozoites ...... ile immunity against infection
@ast
Plasmodium yoelii sporozoites ...... ile immunity against infection
@en
type
label
Plasmodium yoelii sporozoites ...... ile immunity against infection
@ast
Plasmodium yoelii sporozoites ...... ile immunity against infection
@en
prefLabel
Plasmodium yoelii sporozoites ...... ile immunity against infection
@ast
Plasmodium yoelii sporozoites ...... ile immunity against infection
@en
P2093
P2860
P356
P1476
Plasmodium yoelii sporozoites ...... ile immunity against infection
@en
P2093
Anke Harupa
Isabelle Coppens
Mehdi Labaied
Ronald F Dumpit
Sebastian A Mikolajczak
P2860
P304
P356
10.1128/IAI.00225-07
P407
P577
2007-05-21T00:00:00Z